The proteasome: A new target for novel drug therapies

American Journal of Clinical Pathology

Volumn 116, Issue 5, 2001, Pages 637-646

  Elliott, Peter J ^a   Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Arthritis; Asthma; Cancer; HIV; Inflammation; Multiple sclerosis; NF kappa B; PS 341; Psoriasis; Stroke

Indexed keywords

ACLACINOMYCIN; ALDEHYDE DERIVATIVE; BENZAMIDE DERIVATIVE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; CALPASTATIN; CELL PROTEIN; CEP 1612; CVT 634; EPONEMYCIN; EPOXOMYCIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; PROTEASOME; PROTEASOME INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; VINYL DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; ANIMAL MODEL; ARTICLE; ASTHMA; BRAIN INFARCTION; CELL CYCLE; CHRONIC INFLAMMATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG DISPOSITION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PSORIASIS; REPERFUSION INJURY; RHEUMATOID ARTHRITIS; SOLID TUMOR;

ACETYLCYSTEINE; ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CARCINOMA, LEWIS LUNG; CLINICAL TRIALS, PHASE I; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; HUMANS; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 0035736099     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/44HW-5YCJ-FLLP-3R56     Document Type: Article

References (81)

1. The ubiquitin-proteasome proteolytic pathway
2. Proteasomes: Multicatalytic proteinase complexes
3. Functions of the proteasome: The lysis at the end of the tunnel
4. New insights into proteasome function: From archaebacteria to drug development
5. Roles of ubiquitin-mediated proteolysis in cell cycle control
6. Proteasome inhibitors: Valuable new tools for cell biologists
7. Proteasome inhibitors as anti-cancer agents
8. The ubiquitin-proteasome pathway and proteasome inhibitors
9. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
10. A novel and efficient synthesis of a highly active analogue of clastro-lactacystin beta-lactone
11. Eponemycin analogues: Syntheses and use as probes of angiogenesis
12. The antitumor drug aclacinomycin A which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20S proteasome
13. Probing the specificity of the bovine pituitary multicatalytic proteinase complex by inhibitors, activators, and by chemical modifications
14. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex: Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids
15. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
16. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
17. A new structural class of proteasome inhibitors that prevent NF-kappa B activation
18. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides
19. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homologue Hs1 V by a new class of inhibitors
20. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
21. The NF-kappa B and I kappa B proteins: New discoveries and insights
22. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
23. I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations
24. Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: Involvement of NF-kappa B activation in drug resistance
25. Control of inducible chemoresistance: Enhanced antitumor therapy through increased apoptosis by inhibition of NF-kappa B
26. Proteasome inhibitors: From in vitro uses to clinical trials
27. The role of NF-kappaB/IkappaB proteins in cancer: Implications for novel treatment strategies
28. 1- and S-phase regulators
29. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional bcl-2 and p53
30. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
31. Proteasome inhibitors: A novel class of potent and effective antitumor agents
32. The proteasome inhibitor PS-341 in cancer therapy
33. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341
34. Chemosensitization of pancreatic cancer by inhibition of the 26s proteasome
35. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic NF-kappa B inhibition
36. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells
37. 2/M phase arrest and apoptosis induced by PS-341, a novel proteasome inhibitor, are associated with accumulation of p53-related gene products, phosphorylation and cleavage of bcl-2 protein, cytochrome c release, as well as activation of caspase-3, -7, -8, and -9
38. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappa B
39. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
40. Proteasome inhibitor-induced apoptosis in CLL is associated with immediate disruption of mitochondrial function
41. Novel proteasome inhibitor PS-341 inhibits activation of NF-kappa B, cell survival, tumor growth and angiogenesis in squamous cell carcinoma
42. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases
43. Understanding angiogenesis and its clinical applications
44. Tumor angiogenesis: Past, present and the near future
45. The proteasome is involved in angiogenesis
46. Role of the proteasome and NF-kappa B in streptococcal cell wall-induced polyarthritis
47. Proteolysis, proteasomes and antigen presentation
48. Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1
49. Ubiquitin is part of the retrovirus budding machinery
50. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2
51. A role for ubiquitin ligase recruitment in retrovirus release
52. Proteasome inhibition: A novel mechanism to combat asthma
53. Neuroprotection in cerebrovascular disease
54. Brain ischemia and reperfusion: Molecular mechanisms of neuronal injury
55. Is nuclear factor-kappaB a good treatment target in brain ischemia/reperfusion injury?
56. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart
57. Proteasome inhibitor PS-519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia
58. A novel proteasome inhibitor PS-519 inhibits inflammation and affords cerebral neuroprotection against inflammatory mediated ischemic reperfusion injury
59. Proteasome inhibition reduces myocardial reperfusion injury
60. Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappa B activation
61. Postischemic (6h) treatment with rht-PA and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia
62. Inhibition of proteasome reduces iNOS expression and behavioral dysfunction after experimental intracerebral hemorrhage
63. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519
64. Proteasome inhibition reduces superantigen-mediated T-cell activation and severity of psoriasis in a SCID-hu model
65. CLA expression can be regulated at the transcriptional level of FucTVII or by inhibition of O-glycosylation using glycoside based primers
66. Dual roles of proteasome in the metabolism of presenilin 1
67. Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis
68. Proteasome subunits, low-molecular-mass polypeptides 2 and 7 are hyperexpressed by target cells in autoimmune thyroid disease but not in insulin-dependent diabetes mellitus: Implications for autoimmunity
69. Mechanisms of muscle wasting
70. A new model of cancer cachexia: Contribution of the ubiquitin-proteasome pathway
71. Proteasome inhibition attenuates nitric oxide synthetase expression, VCAM-1 transcription and development of chronic colitis
72. Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome
73. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: Toxins, mediators, and modulators of gene expression
74. The ubiquitin-proteasome pathway: Review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions
75. Proteasome a-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus
76. Selective proteasome inhibitors: Modulators of antigen presentation?
77. A proteasome inhibitor effectively prevents mouse heart allograft rejection
78. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer
79. Accurate measurement of proteasome inhibition
80. A phase 1 trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
81. Early clinical experience with the novel proteasome inhibitor PS-519